Third workshop on drugs pricing in Milan

Third workshop on drugs pricing in Milan

The objective of this workshop was achieving a multistakeholder work table discussing about issues related to drugs pricing, focusing the horizon scanning, access to innovation, current and future role of insurances and private providers. This seminar was hold the 4th and 5th of May, 2017 in Mila, Italy, by maprovider . Where Dr. Oriol Solà-Morales gave a talk regarding the decentralized HTA process I the case of...
“Cal definir a l’inici del desenvolupament d’un fàrmac l’estratègia de regulació i esbrinar qui és el client en cada cas”

“Cal definir a l’inici del desenvolupament d’un fàrmac l’estratègia de regulació i esbrinar qui és el client en cada cas”

hitt ha participat a la jornada Lessons Learned: Market Access and Reimbursement organitzada per l’associació d’empreses CataloniaBio i Biocat el passat 29 de novembre al Parc Científic de Barcelona, on també s’han pogut escoltar i debatre les lliçons apreses d’altres experts consultors i de la indústria del sector. Sota la moderació de Pepi Hurtado, PhD – Sòcia, Insights in Life Sciences (ilS), la taula rodona ha comptat com a ponents amb: Antoni Gilabert, gerent de Farmàcia i del Medicament, Servei Català de la Salut Carme Pinyol, directora general, INNOVA-strategic consulting Oriol Solà-Morales, director general, HITT Òscar Pérez, director de Regional access & Business, Celgene Laura E. Ayzin, directora de Relacions institucionals i Market access, Ferrer Les jornades Lessons Learned: Compartint experiències per a impulsar la competitivitat que organitzen l’associació d’empreses CataloniaBio i Biocat són un fòrum de coneixement i networking adreçat als professionals d’empreses de l’àmbit de les ciències de la vida i la salut. Tenen com a objectiu compartir experiències i reflexions en diferents àrees estratègiques de coneixement i capacitats necessàries per reforçar la competitivitat de les empreses biotecnològiques i biomèdiques. CataloniaBio és l’associació d’empreses de l’àmbit de les ciències de la vida i la salut a Catalunya. La seva missió és representar i donar suport a les companyies interessades en promoure un clúster estratègic i innovador, així com participar en la definició del marc d’actuació sectorial i les polítiques industrials que dissenyin tant les administracions del nostre país com les europees. L’associació es va crear el 2006 de la mà d’un grup d’emprenedors, i actualment compta amb més de 90 empreses que tenen una activitat rellevant en R+D+I entre multinacionals, pimes, start-up i spin-off. LLEGIR LA CRÒNICA COMPLETA DE LA...
Spain’s (and Portugal’s) Market Access – update Oct16

Spain’s (and Portugal’s) Market Access – update Oct16

About 60.000 patients treated from HCV infection. Read more. MOH released data on drug access. 59.000 patients treated this year (52.000 F2-F4). Curation rete is at 97% Targeted patients account for 95.000 patients in Spain. The EU Socialist party presents a proposal on innovation at the EU Parliament, and then presents it to the Spanish parliament, where they get support. Read more. ‘…harmonizing the criteria for pricing and reimbursement to take into account the level of innovation and analysis of economic and social profitability, and establish a European classification of the added value of medicines.’ Spanish AEMPS accepts biosimilar indication extrapolation. Read more. Sol Ruiz, Officer from the AEMPS stated last week after the Spanish Rheumatoid Association meeting that “It is possible to extrapolate indications” and referred to the same arguments used to pass the extrapolation of indications of biosimilars” Portuguese Hospitals to be imposed Biosimilar quotas. Read more. Hospitals Portuguese National Health Service (NHS) will have to reach a minimum quota of 20 percent for biosimilars in 2017, as reported by the National Authority of Medicines and Portuguese Health Products (Infarmed) through a statement . In the policy note issued by the Portuguese news agency, ensure that the objective of this measure is to “increase the savings potential of these drugs, optimizing available resources to facilitate the financing of new innovations.”...
Spain’s Market Access – update Sep16

Spain’s Market Access – update Sep16

POLICY Private health expenditure increases 23%: After cuts in public spending, private expenditure has increased by 23%. Read more. Hospital expenditure is reduced by -3.1% in July. For the 7th month in a row, hospital expenditure is reduced. Read more. …while prescription drug expenditure is further increased by 10%: Interanual drug expenditure has expanded +10% according to data from MoH. Read more.   DRUGS MOH: diagnostic drugs ‘can and should go’ to hospital pharmacy. In a recent meeting at Universidad de Santander (UIMP), an officer from MoH declared that they are hoping to shift diagnostic drugs to hospital pharmacy, as this may induce further savings. Read more. Services in Community pharmacies being expanded. Progressive implementation of remunerated tests in community pharmacies, as part of public health programmes. Services are being paid by public insurers. Read more.   INDUSTRY Farmaindustria presented a programme for professionals and patients to improve adherence. They have been preparing with patients and specialists on solutions to improve patients adherence, a major concern for clinicians and payers. Read more Biosimilars Manufacturers request a comprehensive legislative package. After some years in the market, the Industry is demanding a clear regulation. Read more Andalucia’s tendering attracts 16 manufacturers. After their 9th tender for generic drugs, 16 manufacturers applied for the general tender organised by the Region. Read more Seven businesses closing down per day in the last 4 months. Impressive figures on industrial shutdown in the last months. Read more...
Spain’s Market Access update – Aug’16

Spain’s Market Access update – Aug’16

POLICY 70% of the Region’s debt is in Healthcare: total commercial debt to the regions their suppliers rose in May to 9.431 million euros, of which 6.609 million, ie 70%, corresponds to the health sector. Read the Official Ministry Report. Andalucía uses the Electronic prescription to avoid User Charges. As much as 312,000 people a month have avoided having to pay UC when withdrawing a drug. Read more. Valencia is proposing to introduce Therapeutic Equivalents, which beyond the formal definition, include drugs for the same disease with a similar mode of action. Physicians and academic societies are against them. Read more. INDUSTRY Bidafarma is the new wholesaler giant in Andalucía. Read more. Almirall deepens into dermatologic care. It has in-licenced a patent pro Psoriasis. Read the post. DRUGS: Valencia is proposing a network to evaluate and select drugs to be applied across the region. Read more Supreme Court obliges Andalusia to return the compulsory discounts made when naming drugs as Hospital Only. Andalusia has been designating some drugs as HO, entailing them to a compulsory discount. The Supreme Court has ruled that the Region cannot decide which drugs are HO on their own and therefore obliges them to return those discounts to companies. Drug expenditure rose in June16 5’18% more than the previous period last year. New reference groups created 26 new RG have been created, 6 less than the expected There is a RG for vaccines for Varicella, that have been very controversial in the last 2 years. 126 M€ is the estimated impact of these groups. DEVICES: Spanish Agency for Medicines and Health Products (AEMPS) puts in...